BHCM
LNAI

Brevan Howard Capital Management’s Lunai Bioworks LNAI Stock Holding History

Brevan Howard Capital Management’s Portfolio LNAI Stock Details LNAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-408
Closed -$86.5K – 1349
2024
Q1 		$86.5K Buy
+408
New +$110K ﹤0.01% 904

Other funds holding LNAI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Brevan Howard Capital Management's LNAI Position: Q2 2024 in Review

Brevan Howard Capital Management sold out of Lunai Bioworks (LNAI) in Q2 2024, closing a stake of 408 shares — an estimated $86.5K sold.

Brevan Howard Capital Management first reported a position in LNAI in Q1 2024 and held it in 1 quarter. The position peaked at $86.5K in Q1 2024. 39 funds tracked by Wall St. Rank hold LNAI as of Q2 2024.

  • Brevan Howard Capital Management reported no remaining Lunai Bioworks position as of Q2 2024 after selling out during the quarter.
  • Brevan Howard Capital Management sold 408 Lunai Bioworks shares in Q2 2024, an estimated $86.5K.
  • Brevan Howard Capital Management first reported a position in Lunai Bioworks in Q1 2024 and held it in 1 quarter.
  • Brevan Howard Capital Management's Lunai Bioworks position peaked at $86.5K in Q1 2024.
  • 39 funds tracked by Wall St. Rank held Lunai Bioworks as of Q2 2024.

Based on Brevan Howard Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.